Stocktoria
Lyell Immunopharma, Inc. LYEL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-17
Lyell Immunopharma, Inc. statistics & valuation
Market cap$270.9M
P / B1.1×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -748344.4% | -588123.0% | -190006.2% | -220.9% | -2016.7% |
| Net margin | -762355.6% | -562285.2% | -180486.2% | -216.2% | -2349.5% |
| FCF margin | -418900.0% | -266980.3% | -127984.6% | -228.9% | -1800.5% |
| Return on assets | -80.7% | -69.9% | -31.3% | -19.5% | -22.2% |
| Return on equity | -110.6% | -89.6% | -35.8% | -22.0% | -26.9% |
| Current ratio | 5.28 | 7.06 | 16.07 | 17.59 | 13.40 |
| Revenue growth | -41.0% | -53.1% | -99.8% | 695.1% | 37.3% |
Source: SEC EDGAR filings · CIK 0001806952 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.